Education
About Us
Working with TipRanks
Follow Us
Diagnos (TSE:ADK)
:ADK
ADK Stock Chart & Stats
C$0.36
C$0.03(9.38%)
At close: 4:00 PM EST
C$0.36
C$0.03(9.38%)
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.42
Previous CloseN/A
Volume270.50K
Average Volume (3M)342.67K
Market Cap
C$36.12M
Enterprise ValueC$30.93M
Total Cash (Recent Filing)C$737.25K
Total Debt (Recent Filing)C$2.39M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)-6.56
Price to Sales (P/S)117.69
P/FCF Ratio-9.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthcare IT Industry ExposureDiagnos operates in healthcare information services, a structurally growing sector driven by long-term digitization, compliance and data needs. This market positioning supports durable demand for software/services and provides a runway for recurring, sticky revenue if product-market fit and commercial execution improve.
Modest DeleveragingReported reduction in total debt versus the prior annual period indicates management has taken steps to lower leverage. Sustained deleveraging improves solvency, reduces interest burden and lengthens runway, making financing less risky and enhancing flexibility over the medium term.
Signs Of FCF ImprovementThe TTM note of positive free cash flow growth signals initial improvement in operating efficiency or revenue mix. If these improvements persist, they can convert cash burn into stabilizing cash generation, easing financing needs and supporting sustainable operations over several quarters.
Bears Say
Declining Revenue & Weak MarginsRevenue decline and deeply negative gross, EBITDA and net margins show the core business is not covering costs. Persistent negative margins erode competitive position and require either material revenue growth, margin improvements or capital injections to reach sustainable profitability over the medium term.
Negative Shareholders' EquityNegative shareholders' equity signals accumulated losses that impair balance-sheet resilience. This constrains the company's ability to raise non-dilutive capital, increases creditor reliance, and raises the risk of restructuring or dilution if operational improvements don't restore positive equity within several quarters.
Significant Cash BurnSustained negative operating and free cash flow indicate the business is consuming cash rather than funding itself. Continued cash burn requires recurring external financing, which can dilute shareholders or constrain investment in growth initiatives unless cash generation meaningfully improves.
Diagnos News
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.18 and its highest was C$0.41 in the past 12 months.
What is Diagnos’s market cap?
Diagnos’s market cap is C$36.12M.
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Mar 04, 2026 which is in 9 days.
How were Diagnos’s earnings last quarter?
Diagnos released its earnings results on Nov 20, 2025. The company reported -C$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.011.
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Overvalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diagnos have?
Diagnos has 120,412,550 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Diagnos reported an EPS of -C$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diagnos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.04%
Trailing 12-Months
Company Description
Diagnos
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
Technical Analysis
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---